esonide, as the systemic exposure of budesonide may be increased resulting an increase in budesonide-related adverse reactions; use inhaled budesonide with caution, as systemic absorption could increase. Ribociclib is a moderate CYP3A4 inhibitor and budesonide is a CYP3A4 substrate.
Budesonide; Formoterol: (Major) Avoid coadministration of ribociclib with systemic budesonide, as the systemic exposure of budesonide may be increased resulting an increase in budesonide-related adverse reactions; use inhaled budesonide with caution, as systemic absorption could increase. Ribociclib is a moderate CYP3A4 inhibitor and budesonide is a CYP3A4 substrate. (Moderate) Due to a possible risk for QT prolongation, ribociclib and long-acting beta-agonists should be used together cautiously. Beta-agonists may be associated with adverse cardiovascular effects including QT interval prolongation, usually at higher doses, when associated with hypokalemia, or when used with other drugs known to prolong the QT interval like ribociclib. This risk may be more clinically significant with long-acting beta-agonists such as formoterol as compared to short-acting beta-agonists.
Bupivacaine Liposomal: (Moderate) Use caution if coadministration of ribociclib, a moderate CYP3A4 inhibitor, with bupivacaine, a CYP3A4 substrate, is necessary, as the systemic exposure of bupivacaine may be increased resulting in an increase in bupivacaine-related adverse reactions.
Bupivacaine: (Moderate) Use caution if coadministration of ribociclib, a moderate CYP3A4 inhibitor, with bupivacaine, a CYP3A4 substrate, is necessary, as the systemic exposure of bupivacaine may be increased resulting in an increase in bupivacaine-related adverse reactions.
Bupivacaine; Lidocaine: (Moderate) Use caution if coadministration of ribociclib, a moderate CYP3A4 inhibitor, with bupivacaine, a CYP3A4 substrate, is necessary, as the systemic exposure of bupivacaine may be increased resulting in an increase in bupivacaine-related adverse reactions. (Moderate) Use caution if ribociclib is coadministered with lidocaine, as the systemic exposure of lidocaine may increase resulting in lidocaine-related adverse reactions. Adjust the dose of lidocaine if necessary. Ribociclib is a moderate CYP3A4 inhibitor and lidocaine is a CYP3A4 substrate.
Buprenorphine: (Major) Avoid coadministration of ribociclib with buprenorphine due to an increased risk for QT prolongation and torsade de pointes (TdP). Systemic exposure of buprenorphine may also be increased resulting in an increase in buprenorphine-related adverse reactions. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Buprenorphine has been associated with QT prolongation and has a possible risk of TdP. Concomitant use may increase the risk for QT prolongation. Ribociclib is also a moderate CYP3A4 inhibitor and buprenorphine is a CYP3A4 substrate.
Buprenorphine; Naloxone: (Major) Avoid coadministration of ribociclib with buprenorphine due to an increased risk for QT prolongation and torsade de pointes (TdP). Systemic exposure of buprenorphine may also be increased resulting in an increase in buprenorphine-related adverse reactions. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Buprenorphine has been associated with QT prolongation and has a possible risk of TdP. Concomitant use may increase the risk for QT prolongation. Ribociclib is also |
